NO974258D0 - IL-17-reseptor - Google Patents

IL-17-reseptor

Info

Publication number
NO974258D0
NO974258D0 NO974258A NO974258A NO974258D0 NO 974258 D0 NO974258 D0 NO 974258D0 NO 974258 A NO974258 A NO 974258A NO 974258 A NO974258 A NO 974258A NO 974258 D0 NO974258 D0 NO 974258D0
Authority
NO
Norway
Prior art keywords
receptors
receptor
isolated
ctla
inhibit
Prior art date
Application number
NO974258A
Other languages
English (en)
Other versions
NO974258L (no
Inventor
Zhengbin Yao
Melanie K Spriggs
William C Fanslow
Original Assignee
Immunex Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27021039&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO974258(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Immunex Corp filed Critical Immunex Corp
Publication of NO974258D0 publication Critical patent/NO974258D0/no
Publication of NO974258L publication Critical patent/NO974258L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
NO974258A 1995-03-23 1997-09-15 IL-17-reseptor NO974258L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41053595A 1995-03-23 1995-03-23
US53876595A 1995-08-07 1995-08-07
PCT/US1996/004018 WO1996029408A1 (en) 1995-03-23 1996-03-21 Il-17 receptor

Publications (2)

Publication Number Publication Date
NO974258D0 true NO974258D0 (no) 1997-09-15
NO974258L NO974258L (no) 1997-11-24

Family

ID=27021039

Family Applications (1)

Application Number Title Priority Date Filing Date
NO974258A NO974258L (no) 1995-03-23 1997-09-15 IL-17-reseptor

Country Status (15)

Country Link
US (9) US5869286A (no)
EP (1) EP0817847B2 (no)
JP (1) JP4373495B2 (no)
KR (1) KR100467998B1 (no)
AT (1) ATE279517T1 (no)
AU (1) AU696775B2 (no)
CA (1) CA2215394C (no)
DE (1) DE69633617T3 (no)
DK (1) DK0817847T4 (no)
ES (1) ES2229264T5 (no)
MX (1) MX9707021A (no)
NO (1) NO974258L (no)
NZ (1) NZ306653A (no)
PT (1) PT817847E (no)
WO (1) WO1996029408A1 (no)

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6274711B1 (en) 1993-06-14 2001-08-14 Inserm, Institut National De La Sante Et De La Recherche Medicale Purified mammalian CTLA-8 antigens and related reagents
JP4373495B2 (ja) * 1995-03-23 2009-11-25 イミュネックス・コーポレーション Ｉｌ−１７受容体
US6680057B1 (en) * 1995-03-23 2004-01-20 Immunex Corporation Methods of treating autoimmune disease by administering interleukin-17 receptor
US6074849A (en) * 1995-07-19 2000-06-13 Genetics Institute, Inc. Polynucleotides encoding human CTLA-8 related proteins
WO1997004097A2 (en) * 1995-07-19 1997-02-06 Genetics Institute, Inc. Human ctla-8 and uses of ctla-8-related proteins
US6902735B1 (en) 1995-07-19 2005-06-07 Genetics Institute, Llc Antibodies to human IL-17F and other CTLA-8-related proteins
DE69739375D1 (de) * 1996-11-27 2009-06-04 Immunex Corp Verfahren zur regulierung der stickstoffmonoxid-erzeugung
US7005412B1 (en) * 1996-11-27 2006-02-28 Immunex Corporation Method of treating ulcerative colitis and Crohn's disease using IL-17 receptor proteins
US6579520B2 (en) * 1998-05-15 2003-06-17 Genentech, Inc. IL-17 related mammalian cytokine polypeptides (IL-17E)
US6849719B2 (en) 1997-09-17 2005-02-01 Human Genome Sciences, Inc. Antibody to an IL-17 receptor like protein
US6635443B1 (en) 1997-09-17 2003-10-21 Human Genome Sciences, Inc. Polynucleotides encoding a novel interleukin receptor termed interleukin-17 receptor-like protein
US6482923B1 (en) * 1997-09-17 2002-11-19 Human Genome Sciences, Inc. Interleukin 17-like receptor protein
NZ505710A (en) * 1997-12-22 2003-03-28 Stiftelsen Universitetsforskni Human Fc receptor genotypes that correspond to the benign/non benign nature of selected autoimmune diseases
WO1999035263A2 (en) * 1998-01-09 1999-07-15 Immunex Corporation Il-17rh dna and polypeptides
US7771719B1 (en) 2000-01-11 2010-08-10 Genentech, Inc. Pharmaceutical compositions, kits, and therapeutic uses of antagonist antibodies to IL-17E
JP3577586B2 (ja) 1998-05-15 2004-10-13 ジェネンテック・インコーポレーテッド Ｉｌ−１７相同的ポリペプチドとその治療用途
US20050147609A1 (en) * 1998-05-15 2005-07-07 Genentech, Inc. Use of anti-IL-17 antibody for the treatment of cartilage damaged by osteoarthritis
US8133734B2 (en) 1999-03-16 2012-03-13 Human Genome Sciences, Inc. Kit comprising an antibody to interleukin 17 receptor-like protein
EP1171109A1 (en) * 1999-04-14 2002-01-16 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Compositions containing immunotoxins and agents that inhibit dendritic cell maturation for inducing immune tolerance to a graft
WO2000064327A2 (en) * 1999-04-26 2000-11-02 Duke University Inhibition of complement action
US6936424B1 (en) * 1999-11-16 2005-08-30 Matritech, Inc. Materials and methods for detection and treatment of breast cancer
DK1897944T3 (da) * 1999-12-23 2011-10-24 Genentech Inc IL-17 homologe polypeptider og terapeutisk anvendelse deraf
ATE519847T1 (de) * 1999-12-23 2011-08-15 Genentech Inc Il-17-homologe polypeptide und ihre therapeutische verwendung
US20040043397A1 (en) 2000-01-11 2004-03-04 Genentech, Inc. IL-17 homologous polypeptides and therapeutic uses thereof
JP2016047051A (ja) * 1999-12-23 2016-04-07 ジェネンテック， インコーポレイテッド Ｉｌ−１７相同的ポリペプチドとその治療上の用途
AR028256A1 (es) * 2000-03-16 2003-04-30 Amgen Inc Moleculas similares a receptores il-17 y usos de las mismas
US7718397B2 (en) 2000-03-21 2010-05-18 Genentech, Inc. Nucleic acids encoding receptor for IL-17 homologous polypeptides and uses thereof
JP2003534013A (ja) * 2000-05-24 2003-11-18 シェーリング コーポレイション 哺乳動物レセプタータンパク質；関連試薬および方法
ES2614260T3 (es) 2000-05-26 2017-05-30 Immunex Corporation Uso de anticuerpos contra el receptor de interleuquina-4 y composiciones de los mismos
US20030096969A1 (en) 2000-06-02 2003-05-22 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20020146763A1 (en) * 2000-07-06 2002-10-10 Zeren Gao Murine cytokine receptor
AU2001277980A1 (en) * 2000-07-26 2002-02-05 Zymogenetics Inc. Human cytokine receptor
EP1326626B1 (en) * 2000-10-18 2020-04-01 Immunex Corporation Methods for treating rheumatoid arthritis using il-17 antagonists
WO2002038764A2 (en) * 2000-11-10 2002-05-16 The Regents Of The University Of California Il-17 receptor-like protein, uses thereof, and modulation of catabolic activity of il-17 cytokines on bone and cartilage
US20040136992A1 (en) 2002-08-28 2004-07-15 Burton Paul B. J. Compositions and method for treating cardiovascular disease
EP2322203A3 (en) * 2002-10-29 2011-07-27 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
JP4441170B2 (ja) * 2002-11-28 2010-03-31 独立行政法人理化学研究所 Ｓ１２リボソームタンパク質に変異を有する大腸菌細胞抽出液及びそれを用いる無細胞系によるタンパク質の製造方法
DK1670511T3 (da) * 2003-09-15 2009-11-23 Res Dev Foundation Cripto-antagonisme af activin- og TGF-B-signalering
US20080014172A1 (en) * 2004-05-28 2008-01-17 Applied Research Systems Ars Holding N.V. Use of Il-17 in the Treatment of Fertility-Related Disorders
US7910540B2 (en) 2004-06-10 2011-03-22 Zymogenetics, Inc. Soluble ZcytoR14, anti-ZcytoR14 antibodies and binding partners and methods of using in inflammation
GB0417487D0 (en) 2004-08-05 2004-09-08 Novartis Ag Organic compound
US20060068434A1 (en) * 2004-09-21 2006-03-30 Jay Stoerker Methods and compositions for detecting cancer using components of the U2 spliceosomal particle
WO2006044840A2 (en) * 2004-10-18 2006-04-27 Zymogenetics, Inc. Soluble zcytor21, anti-zcytor21 antibodies and binding partners and methods of using in inflammation
JP4868731B2 (ja) 2004-11-17 2012-02-01 独立行政法人理化学研究所 哺乳動物培養細胞由来の無細胞タンパク質合成システム
JP4590249B2 (ja) * 2004-11-17 2010-12-01 独立行政法人理化学研究所 糖タンパク質合成用の無細胞タンパク質合成システム
JP4787488B2 (ja) * 2004-11-19 2011-10-05 独立行政法人理化学研究所 直鎖状鋳型ｄｎａを用いた無細胞タンパク質合成方法及びそのための細胞抽出液
AU2006214473A1 (en) * 2005-02-14 2006-08-24 Wyeth Interleukin-17F antibodies and other IL-17F signaling antagonists and uses therefor
BRPI0608210A2 (pt) * 2005-02-14 2010-11-09 Wyeth Corp métodos de diagnóstico de um distúrbio relacionado com il-17f em um indivìduo e de seleção de compostos capazes de inibirem a ligação de il-17f em il-17r, uso de um antagonista de il-17f, composição farmacêutica, e, adjuvante de vacina
GB0504436D0 (en) * 2005-03-03 2005-04-06 Glaxosmithkline Biolog Sa Vaccine
EP1909831A4 (en) 2005-06-14 2013-02-20 Amgen Inc PREPARATIONS OF SPONTANEOUS TAMPING PROTEINS
JP2009507023A (ja) 2005-09-01 2009-02-19 シェーリング コーポレイション 自己免疫性眼炎症性疾患を処置するためのｉｌ−２３およびｉｌ−１７のアンタゴニストの使用
US20070249533A1 (en) 2005-09-28 2007-10-25 Levin Steven D Il-17a and il-17f antagonists and methods of using the same
CA2638864A1 (en) * 2006-02-10 2007-10-18 Zymogenetics, Inc. Truncated il-17ra soluble receptor and methods of using in inflammation
WO2008039553A1 (en) 2006-02-10 2008-04-03 Zymogenetics, Inc. Soluble il-17rcx4 and methods of using in inflammation
AU2007261019A1 (en) * 2006-06-19 2007-12-27 Wyeth Methods of modulating IL-22 and IL-17
US7833527B2 (en) * 2006-10-02 2010-11-16 Amgen Inc. Methods of treating psoriasis using IL-17 Receptor A antibodies
FR2908999B1 (fr) * 2006-11-29 2012-04-27 Biomerieux Sa Nouveau medicament destine a l'inhibition, la prevention ou le traitement de la polyarthrite rhumatoide.
FR2910324B1 (fr) * 2006-12-21 2009-03-06 Biomerieux Sa Nouveau medicament pour le traitement d'un cancer gastrique
NZ579297A (en) 2007-02-28 2012-03-30 Schering Corp Combination therapy comprising an il-23 antagonist and a cytokine antagonist for treatment of immune disorders
CN101679497A (zh) 2007-03-26 2010-03-24 津莫吉尼蒂克斯公司 可溶性il-17ra/rc融合蛋白以及相关方法
CL2008000883A1 (es) * 2007-03-28 2008-10-03 Wyeth6 3 Metodo de deteccion de compuestos capaces de antagonizar la senalizacion de il-17f/il-17a; compuesto identificado por dicho metodo; uso de una cantidad de un antagonista de senalizacion de il-17f/il-17a, composicion farmaceutica que comprende dicho a
AU2008242665B2 (en) * 2007-04-20 2013-09-05 Amgen Inc. Identification and method for using the Pre-Ligand Assembly Domain of the IL-17 receptor
ES2614735T3 (es) * 2007-07-23 2017-06-01 Janssen Biotech, Inc. Métodos y composiciones para tratar los trastornos relacionados con fibrosis usando antagonistas de la IL-17
EP2203476B1 (en) * 2007-09-25 2016-10-26 Genzyme Corporation Compositions and methods for inhibiting interleukin pathways
EP2213747B1 (en) * 2007-11-05 2021-06-30 Riken Method for producing membrane protein
BRPI0907196B1 (pt) * 2008-02-21 2021-05-25 Kirin-Amgen Inc Uso de um antagonista de il-17ra-il-17rb
WO2009136286A2 (en) * 2008-05-05 2009-11-12 Novimmune Sa Anti-il-17a/il-17f cross-reactive antibodies and methods of use thereof
EP2166358A1 (en) * 2008-09-17 2010-03-24 Fundacio Institut de Recerca de l'Hospital Universitari Vall d'Hebron Differential diagnostic biomarkers of stroke mimicking conditions and methods of use thereof
US20100233270A1 (en) 2009-01-08 2010-09-16 Northwestern University Delivery of Oligonucleotide-Functionalized Nanoparticles
US8734796B2 (en) 2009-03-20 2014-05-27 Amgen Inc. Carrier immunoglobulins
WO2010128407A2 (en) 2009-05-05 2010-11-11 Novimmune S.A. Anti-il-17f antibodies and methods of use thereof
AU2010303166A1 (en) * 2009-10-10 2012-05-24 Eleven Biotherapeutics, Inc. IL-17 family cytokine compositions and uses
TW201117824A (en) 2009-10-12 2011-06-01 Amgen Inc Use of IL-17 receptor a antigen binding proteins
MY182680A (en) 2010-01-15 2021-01-29 Amgen K A Inc Antibody formulation and therapeutic regimens
WO2012040518A2 (en) * 2010-09-22 2012-03-29 Amgen Inc. Carrier immunoglobulins and uses thereof
JP6038884B2 (ja) 2011-04-20 2016-12-07 アムゲン・インコーポレーテッド 自動式注射装置
US20140234330A1 (en) 2011-07-22 2014-08-21 Amgen Inc. Il-17 receptor a is required for il-17c biology
WO2013116682A1 (en) 2012-02-02 2013-08-08 Ensemble Therapeutics Corporation Macrocyclic compounds for modulating il-17
JP6768501B2 (ja) 2013-03-15 2020-10-14 アムゲン・インコーポレーテッド 薬物カセット、自動注入機、および自動注入機システム
JP6336564B2 (ja) 2013-03-15 2018-06-06 アムゲン・インコーポレーテッド 薬物カセット、自動注入器、および自動注入器システム
US20170174772A1 (en) 2014-03-31 2017-06-22 Kirin-Amgen, Inc. Methods of treating nail and scalp psoriasis
CA3032514C (en) 2015-07-31 2021-05-04 Takehiro SHINODA Method of producing membrane protein and utilization thereof
US11866700B2 (en) 2016-05-06 2024-01-09 Exicure Operating Company Liposomal spherical nucleic acid (SNA) constructs presenting antisense oligonucleotides (ASO) for specific knockdown of interleukin 17 receptor mRNA
WO2018018082A1 (en) 2016-07-26 2018-02-01 The Australian National University Immunostimulatory compositions and uses therefor
WO2018201090A1 (en) 2017-04-28 2018-11-01 Exicure, Inc. Synthesis of spherical nucleic acids using lipophilic moieties
MA50903A (fr) 2017-11-16 2021-05-12 Amgen Inc Auto-injecteur avec détection de décrochage et de point d'extrémité
CN114164177A (zh) 2019-01-17 2022-03-11 百奥赛图(北京)医药科技股份有限公司 人源化转基因动物
JP2022547678A (ja) 2019-09-11 2022-11-15 ボシュ ヘルス アイルランド リミテッド Ｉｌ－１７ｒａ抗体を用いた非アルコール性脂肪性肝疾患（ｎａｆｌｄ）の治療方法
JP2022176672A (ja) * 2021-05-17 2022-11-30 国立大学法人北海道大学 ペプチド及び医薬用組成物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5116964A (en) * 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5703088A (en) * 1989-08-21 1997-12-30 Beth Israel Deaconess Medical Center, Inc. Topical application of spiperone or derivatives thereof for treatment of pathological conditions associated with immune responses
US5716805A (en) * 1991-10-25 1998-02-10 Immunex Corporation Methods of preparing soluble, oligomeric proteins
US6562333B1 (en) * 1993-06-14 2003-05-13 Schering Corporation Purified mammalian CTLA-8 antigens and related reagents
US6274711B1 (en) * 1993-06-14 2001-08-14 Inserm, Institut National De La Sante Et De La Recherche Medicale Purified mammalian CTLA-8 antigens and related reagents
JP4373495B2 (ja) * 1995-03-23 2009-11-25 イミュネックス・コーポレーション Ｉｌ−１７受容体
US6074849A (en) * 1995-07-19 2000-06-13 Genetics Institute, Inc. Polynucleotides encoding human CTLA-8 related proteins
DE69739375D1 (de) * 1996-11-27 2009-06-04 Immunex Corp Verfahren zur regulierung der stickstoffmonoxid-erzeugung
EP1326626B1 (en) * 2000-10-18 2020-04-01 Immunex Corporation Methods for treating rheumatoid arthritis using il-17 antagonists

Also Published As

Publication number Publication date
US6197525B1 (en) 2001-03-06
ES2229264T3 (es) 2005-04-16
DK0817847T3 (da) 2005-02-14
NZ306653A (en) 1999-03-29
DE69633617T3 (de) 2010-05-20
US20100233186A1 (en) 2010-09-16
CA2215394A1 (en) 1996-09-26
ATE279517T1 (de) 2004-10-15
EP0817847B1 (en) 2004-10-13
ES2229264T5 (es) 2009-12-17
DE69633617D1 (de) 2004-11-18
US6100235A (en) 2000-08-08
KR19980703061A (ko) 1998-09-05
WO1996029408A1 (en) 1996-09-26
US5869286A (en) 1999-02-09
DK0817847T4 (da) 2009-10-05
JPH11503309A (ja) 1999-03-26
JP4373495B2 (ja) 2009-11-25
US6191104B1 (en) 2001-02-20
NO974258L (no) 1997-11-24
US6096305A (en) 2000-08-01
MX9707021A (es) 1997-11-29
EP0817847B2 (en) 2009-09-09
US20090068737A1 (en) 2009-03-12
KR100467998B1 (ko) 2005-11-25
EP0817847A1 (en) 1998-01-14
PT817847E (pt) 2005-02-28
US6072033A (en) 2000-06-06
CA2215394C (en) 2011-04-26
AU5526396A (en) 1996-10-08
DE69633617T2 (de) 2005-11-03
US6072037A (en) 2000-06-06
AU696775B2 (en) 1998-09-17

Similar Documents

Publication Publication Date Title
DE69633617D1 (de) Il-17 receptor
LU91758I9 (no)
ATE360032T1 (de) Cystein-reiche rezeptoren-train
FI972945A (fi) Antigeenien antamiseen soveltuvia koostumuksia
EP0837927A4 (en) MONOCLONAL MONKEY ANTIBODIES AGAINST HUMANE B7.1 AND / OR B7.2 ANTIGEN, PRIMATIZED DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS
IS4565A (is) 2-methýl-thíenó-bensódíasepín, samsetning til inntöku
FR2705566B1 (fr) Nouvelles compositions pharmaceutiques.
ITRM920476A0 (it) Formulazioni galeniche contenenti ciclosporina.
DE69226431D1 (de) Zellrezeptor spezifische monoklonale antikörper gegen stammzell-faktor-rezeptor
IS4706A (is) Lyfjasamsetningar
TR199600786T1 (tr) Agiz yoluyla alinan yeni farmasötik dozaj formlari.
IT8920486A0 (it) Composizioni farmaceutiche.
FI893643A (fi) Farmaceutiska kompositioner.
DE69007908T2 (de) Shampoo-Zusammensetzung.
SE9802937D0 (sv) Novel compounds
DE69600598T2 (de) Brennstoffzusammensetzungen
IT1288164B1 (it) Dispositivo di regolazione dell'altezza della spalliera dello schienale,in particolare in sedie da ufficio.
FR2674755B1 (fr) Nouvelles compositions medicamenteuses immunostimulatrices.
TR199800152T1 (xx) Endotelin Resept�r Antagonistleri
ITRM920845A0 (it) Composizioni cementizie.
DE69526738D1 (de) Endothelin-rezeptor-antagonisten
DE69614552T2 (de) MODIFIZIERTE ALPHA-D-GLCP-(1,2)-ALPHA-D-Glcp-(1,3)-ALPHA-D-Glcp-ANALOGE
FI920845A0 (fi) Farmaceutiska kompositioner innehaollande interleukin-2.
IT1294932B1 (it) Uso di 2-amminotetraline-6,7 sostituite per la preparazione di composizioni farmaceutiche atte al trattamento di patologie
DE69200508T2 (de) Modifiziertes Aethylen-alpha-olefin-nichtkonjugiertes Dien Copolymer Elastomer Zusammensetzung.